Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Goes All In With Asundexian And Pulls Two Other Factor XIa Projects

Potential Xarelto Successor Prioritized

Executive Summary

Despite promising mid-stage data for the Ionis-partnered fesomersen and osocimab, licensed from Aronora, the German major has plumped for asundexian as the priority compound for its Factor XIa efforts.

You may also be interested in...



High-Dose Eylea’s Improved Durability Could Protect Regeneron’s Market Share

The US firm’s high-dose reformulation of Eylea reduced dosing burden for patients with DME and wet AMD in two pivotal studies and could match Roche’s rival drug.

Confidence In Factor XIa Inhibition Wavers After Bristol/Janssen And Bayer Data

BMS/Janssen’s milvexian and Bayer’s asundexian prevented strokes without major increases in severe bleeding and no fatal bleeds but Phase III outcomes are uncertain based on mixed Phase II data.

Bayer Outlines Asundexian Phase III Plan, Hoping To Prove Safety Benefit Over Eliquis

The Factor XIa inhibitor could be an effective anticoagulant without the increased risk in bleeding associated with current Factor Xa inhibitors, but the profile will need to be confirmed in Phase III.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel